Commentary
Regulator or regulatory shield? The case for reforming Canada’s Patented Medicine Prices Review Board
Rujun Zhang, Danielle Martin and C. David Naylor
CMAJ April 10, 2017 189 (14) E515-E516; DOI: https://doi.org/10.1503/cmaj.161355
Rujun Zhang
Family and Community Medicine (Zhang), Women’s College Hospital; Medical Affairs and Health System Solutions (Martin), Women’s College Hospital; Department of Family and Community Medicine, and Institute of Health Policy, Management and Evaluation (Martin), University of Toronto; Department of Medicine and Institute of Health Policy, Management and Evaluation (Naylor), University of Toronto, Toronto, Ont.
MDDanielle Martin
Family and Community Medicine (Zhang), Women’s College Hospital; Medical Affairs and Health System Solutions (Martin), Women’s College Hospital; Department of Family and Community Medicine, and Institute of Health Policy, Management and Evaluation (Martin), University of Toronto; Department of Medicine and Institute of Health Policy, Management and Evaluation (Naylor), University of Toronto, Toronto, Ont.
MDC. David Naylor
Family and Community Medicine (Zhang), Women’s College Hospital; Medical Affairs and Health System Solutions (Martin), Women’s College Hospital; Department of Family and Community Medicine, and Institute of Health Policy, Management and Evaluation (Martin), University of Toronto; Department of Medicine and Institute of Health Policy, Management and Evaluation (Naylor), University of Toronto, Toronto, Ont.
MD DPhilIn this issue
Article tools
Regulator or regulatory shield? The case for reforming Canada’s Patented Medicine Prices Review Board
Rujun Zhang, Danielle Martin, C. David Naylor
CMAJ Apr 2017, 189 (14) E515-E516; DOI: 10.1503/cmaj.161355
Related Articles
- No related articles found.